A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations
This research study tests a targeted cancer-fighting medication called belzutifan. It aims to see how well this medicine works and if it is safe for people with specific rare tumors or genetic conditions.
You may be able to join if you are 12 years or older and have been diagnosed with one of the specific advanced tumor types or genetic conditions included in the study, such as von Hippel-Lindau disease. However, you cannot join if you have low blood oxygen, recent heart issues, or trouble swallowing pills.
Participants will take the study drug, belzutifan, which is a pill. Doctors will regularly check your health and scan your tumors to see how well the treatment is working.
This study is currently recruiting patients at various locations, including Los Angeles and Chicago in the United States. Your care team will let you know which specific clinic is closest to you.
- 1Testing a targeted cancer medicine called belzutifan taken as a pill
- 2Open to patients 12 and older with specific rare tumors or genetic conditions
- 3Currently recruiting participants at select locations in the United States
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.